At present, the ability to determine the clinical expression of TEM-1 in patients with metastatic disease relies on IHC of biopsies of single lesions or primary tumors that may not represent true TEM-1 expression when compared to the total tumor burden in a patient. The gene discussed is CD248; the disease is metastatic neoplasm.